Your browser is no longer supported. Please, upgrade your browser.
AXGT Axovant Gene Therapies Ltd. daily Stock Chart
Axovant Gene Therapies Ltd.
Index- P/E- EPS (ttm)-1.96 Insider Own0.20% Shs Outstand43.29M Perf Week0.00%
Market Cap159.05M Forward P/E- EPS next Y-1.37 Insider Trans121.98% Shs Float28.55M Perf Month-19.65%
Income-53.20M PEG- EPS next Q-0.33 Inst Own26.70% Short Float1.84% Perf Quarter19.48%
Sales- P/S- EPS this Y63.50% Inst Trans0.30% Short Ratio0.39 Perf Half Y11.52%
Book/sh1.35 P/B2.73 EPS next Y-14.20% ROA-75.10% Target Price- Perf Year-30.57%
Cash/sh1.28 P/C2.87 EPS next 5Y- ROE-149.50% 52W Range1.41 - 6.93 Perf YTD-28.12%
Dividend- P/FCF- EPS past 5Y-10.10% ROI- 52W High-46.90% Beta1.30
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low160.99% ATR0.45
Employees38 Current Ratio4.90 Sales Q/Q- Oper. Margin- RSI (14)46.75 Volatility8.49% 11.69%
OptionableYes Debt/Eq0.00 EPS Q/Q83.90% Profit Margin- Rel Volume1.10 Prev Close3.61
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume1.34M Price3.68
Recom1.60 SMA20-12.83% SMA501.30% SMA2008.33% Volume1,470,176 Change1.94%
Apr-17-20Initiated Cantor Fitzgerald Overweight $11
Oct-28-19Reiterated Chardan Capital Markets Buy $10 → $15
Aug-12-19Upgrade Robert W. Baird Neutral → Outperform $16 → $13
Jun-21-19Initiated SVB Leerink Outperform $18
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Upgrade Chardan Capital Markets Neutral → Buy $4
Oct-13-20 07:00AM  
Oct-12-20 01:04PM  
Oct-09-20 07:00AM  
Oct-08-20 08:52AM  
Oct-06-20 07:00AM  
Oct-05-20 07:00AM  
Oct-03-20 06:07AM  
Sep-22-20 08:56AM  
Sep-15-20 08:00AM  
Sep-10-20 08:33AM  
Sep-08-20 07:30AM  
Aug-11-20 07:00AM  
Jul-31-20 07:45AM  
Jul-13-20 07:02PM  
Jul-05-20 08:46PM  
Jun-24-20 12:00AM  
Jun-10-20 06:00AM  
Jun-08-20 07:30AM  
Jun-02-20 12:00PM  
May-28-20 08:00AM  
May-18-20 11:43AM  
May-12-20 01:40PM  
May-07-20 08:00AM  
May-05-20 10:55AM  
Apr-24-20 07:30AM  
Apr-15-20 08:00AM  
Apr-08-20 12:00PM  
Mar-31-20 08:00AM  
Mar-10-20 06:46AM  
Feb-24-20 04:01PM  
Feb-19-20 10:11PM  
Feb-10-20 06:00AM  
Jan-13-20 06:30AM  
Jan-06-20 12:00PM  
Dec-23-19 02:19PM  
Dec-20-19 08:12AM  
Dec-19-19 05:41PM  
Dec-03-19 07:00AM  
Nov-19-19 09:40AM  
Nov-18-19 07:30AM  
Nov-14-19 08:34AM  
Nov-13-19 09:00AM  
Nov-08-19 08:00AM  
Nov-05-19 08:00AM  
Oct-23-19 07:00AM  
Oct-20-19 08:08AM  
Oct-10-19 08:00AM  
Oct-09-19 09:00AM  
Sep-27-19 05:45PM  
Sep-25-19 04:05PM  
Sep-19-19 05:50PM  
Sep-13-19 05:45PM  
Sep-12-19 09:15AM  
Aug-12-19 05:48PM  
Aug-09-19 07:00AM  
Aug-08-19 10:45AM  
Aug-02-19 10:48AM  
Jul-29-19 05:50PM  
Jul-16-19 08:17AM  
Jul-12-19 05:45PM  
Jul-10-19 07:04AM  
Jul-08-19 09:55AM  
Jul-03-19 02:19PM  
Jul-01-19 07:00AM  
Jun-28-19 08:35PM  
Jun-26-19 08:58AM  
Jun-24-19 07:01AM  
Jun-21-19 03:35PM  
Jun-20-19 09:42AM  
Jun-14-19 09:00AM  
Jun-11-19 06:18PM  
Jun-06-19 07:40AM  
Jun-04-19 04:16PM  
May-31-19 07:00AM  
May-30-19 08:44AM  
May-29-19 10:40AM  
May-28-19 09:02AM  
May-27-19 05:00AM  
May-21-19 05:34AM  
May-20-19 03:06PM  
May-17-19 05:33PM  
May-16-19 04:05PM  
May-14-19 09:05AM  
May-07-19 04:15PM  
Apr-30-19 07:00AM  
Apr-25-19 02:35PM  
Apr-16-19 07:00AM  
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pande AtulDirectorJul 08Buy2.7310,00027,29023,370Jul 10 06:12 PM
Cheruvu PavanPrincipal Executive OfficerJul 08Buy2.7437,500102,63857,836Jul 10 06:11 PM
Pande AtulDirectorMar 16Buy1.7810,00017,84413,370Mar 18 08:20 PM
Roivant Sciences Ltd.10% OwnerFeb 24Buy3.755,333,33319,999,99918,577,380Feb 27 07:49 PM